All In Biotech

Drug Trial Radar · NCT03347396

A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study)

A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion

Last checked: Nov 20, 2026Latest source record: Oct 31, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Title says "pivotal". This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

24

Actual

Start

Mar 5, 2018

Primary completion

Oct 5, 2021

Study completion Oct 5, 2021

Sponsor

Lead sponsor
Bioverativ, a Sanofi companySanofi (SNY)
Sponsor type
Industry
First posted
Nov 20, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of Part A was to determine whether sutimlimab administration resulted in a greater than or equal to (\>=) 2 grams per deciliter (g/dL) increase in hemoglobin (Hgb) levels or increased Hgb to \>= 12 g/dL and obviated the need for blood transfusion during treatment in participants with primary cold agglutinin disease (CAD) who had a recent history of blood transfusion. The purpose of Part B was to evaluate the long-term safety and tolerability of sutimlimab in participants with CAD.

Conditions

  • Agglutinin Disease, Cold

Interventions

  • BIVV009Drug

    Sutimlimab was administered as intravenous (IV) infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Percentage of Participants With Response to TreatmentTime frame: From Week 5 through Week 26
  2. Part B: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)Time frame: Part B, 6.5 g cohort: From first dose (Week 27) up to 143 weeks of treatment + 9 weeks of follow-up (i.e., up to Week 179); Part B, 7.5 g cohort: From first dose (Week 27) up to 149 weeks of treatment + 9 weeks of follow-up (i.e., up to Week 185)

Locations

49 sites in 14 countries. Site status is shown where the registry gives one.

  • Arizona Oncology Associates PC

    Tucson, Arizona

  • USC/Keck School of Medicine

    Los Angeles, California

  • The Oncology Institute of Hope and Innovation

    Whittier, California

  • Georgetown University Medical Center

    Georgetown, District of Columbia

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Montefiore Medical Center

    New York, New York

  • New York Medical College at Westchester Medical Center

    Valhalla, New York

  • East Carolina University

    Greenville, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • UW Hospitals and Clinics

    Madison, Wisconsin

  • USC Health Clinics

    Buderim, Queensland, Australia

  • Ballarat Oncology & Haematology

    Ballarat, Victoria, Australia

  • Monash Medical Centre

    Clayton, Victoria, Australia

  • Medical University of Vienna

    Vienna, Austria

  • ZNA Stuivenberg

    Antwerp, Belgium

  • Centre Hospitalier Jolimont

    La Louvière, Belgium

  • University Hospitals Leuven

    Leuven, Belgium

  • University of Alberta

    Edmonton, Canada

  • St. Michael's Hospital

    Toronto, Ontario, Canada

  • McGill University Health Center

    Montreal, Quebec, Canada

  • CHU de Caen

    Caen, France

  • Centre Hospitalier Henri Mondor

    Créteil, France

  • Centre Hospitalier Lyon Sud

    Lyon, France

  • Gemeinschaftspraxis Hämatologie-Onkologie

    Dresden, Germany

  • Universitätsklinikum Essen

    Essen, Germany

  • Univ Ulm, Inst Klin. Transfusions. Immungen

    Ulm, Germany

  • Hadassah Medical Center

    Jerusalem, Israel

  • Laniado Hospital

    Netanya, Israel

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel

  • A. O. Spedali Civili di Brescia

    Brescia, Italy

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

    Milan, Italy

  • U.O.C. Ematologia- Policlinico "A. Gemelli"

    Rome, Italy

  • U.O.C. Ematologia Ospedale San Bortolo

    Vicenza, Italy

  • Tokai University Hospital

    Isehara, Kanagawa, Japan

  • Saitama Medical University Hospital

    Iruma-gun, Saitama, Japan

  • Juntendo University Nerima Hospital

    Tokyo, Tokyo-To, Japan

  • Academisch Medisch Centrum

    Amsterdam, Netherlands

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.